Innoviva (INVA) Competitors

In the previous week, Liquidia had 28 more articles in the media than Innoviva. MarketBeat recorded 31 mentions for Liquidia and 3 mentions for Innoviva. Liquidia's average media sentiment score of 0.61 beat Innoviva's score of 0.46 indicating that Liquidia is being referred to more favorably in the news media.

Innoviva has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

Innoviva currently has a consensus target price of $39.00, suggesting a potential upside of 104.94%. Liquidia has a consensus target price of $75.23, suggesting a potential upside of 31.04%. Given Innoviva's stronger consensus rating and higher probable upside, equities analysts clearly believe Innoviva is more favorable than Liquidia.

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 2.0% of Innoviva shares are owned by insiders. Comparatively, 25.6% of Liquidia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Innoviva has higher revenue and earnings than Liquidia. Innoviva is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Innoviva has a net margin of 44.13% compared to Liquidia's net margin of -15.15%. Liquidia's return on equity of 264.65% beat Innoviva's return on equity.

Innoviva has higher earnings, but lower revenue than Organon & Co.. Innoviva is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Innoviva has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market.

Innoviva has a net margin of 44.13% compared to Organon & Co.'s net margin of 3.49%. Organon & Co.'s return on equity of 82.06% beat Innoviva's return on equity.

In the previous week, Organon & Co. had 3 more articles in the media than Innoviva. MarketBeat recorded 6 mentions for Organon & Co. and 3 mentions for Innoviva. Organon & Co.'s average media sentiment score of 0.51 beat Innoviva's score of 0.46 indicating that Organon & Co. is being referred to more favorably in the news media.

Innoviva presently has a consensus target price of $39.00, indicating a potential upside of 104.94%. Organon & Co. has a consensus target price of $12.00, indicating a potential downside of 13.64%. Given Innoviva's stronger consensus rating and higher possible upside, research analysts plainly believe Innoviva is more favorable than Organon & Co..

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 2.0% of Innoviva shares are owned by insiders. Comparatively, 1.6% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Innoviva has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

Innoviva currently has a consensus target price of $39.00, suggesting a potential upside of 104.94%. Tarsus Pharmaceuticals has a consensus target price of $104.57, suggesting a potential upside of 30.26%. Given Innoviva's stronger consensus rating and higher possible upside, equities analysts plainly believe Innoviva is more favorable than Tarsus Pharmaceuticals.

99.1% of Innoviva shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 2.0% of Innoviva shares are held by insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Innoviva has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

In the previous week, Tarsus Pharmaceuticals had 1 more articles in the media than Innoviva. MarketBeat recorded 4 mentions for Tarsus Pharmaceuticals and 3 mentions for Innoviva. Tarsus Pharmaceuticals' average media sentiment score of 0.60 beat Innoviva's score of 0.46 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Innoviva has a net margin of 44.13% compared to Tarsus Pharmaceuticals' net margin of -102.93%. Innoviva's return on equity of 22.91% beat Tarsus Pharmaceuticals' return on equity.

In the previous week, Innoviva and Innoviva both had 3 articles in the media. Indivior's average media sentiment score of 1.11 beat Innoviva's score of 0.46 indicating that Indivior is being referred to more favorably in the news media.

Innoviva has higher earnings, but lower revenue than Indivior. Indivior is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Innoviva has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Indivior has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market.

Innoviva has a net margin of 44.13% compared to Indivior's net margin of 32.75%. Innoviva's return on equity of 22.91% beat Indivior's return on equity.

Innoviva presently has a consensus price target of $39.00, indicating a potential upside of 104.94%. Indivior has a consensus price target of $46.40, indicating a potential upside of 64.48%. Given Innoviva's higher probable upside, equities analysts plainly believe Innoviva is more favorable than Indivior.

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 2.0% of Innoviva shares are owned by insiders. Comparatively, 0.7% of Indivior shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.